Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies. J Invest Dermatol 2025 Jun;145(6):1294-1304
Date
11/13/2024Pubmed ID
39530954DOI
10.1016/j.jid.2024.09.017Scopus ID
2-s2.0-85208676459 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is associated with significant morbidity despite therapeutic advances. Distinct clinical phenotypes have emerged, which can correlate with myositis-specific antibodies. Because translational data solidify the role of type I IFNs in JDM disease pathogenesis, integration of clinical and molecular phenotyping may impact the choice of targeted therapy. This paper reviews clinical and molecular phenotyping in JDM and translational insights into immune pathogenesis that have created emerging options for targeted therapy.
Author List
Chen KL, Chiu YE, Vleugels RA, Co DO, Kim H, Sabbagh SE, Arkin LMAuthors
Yvonne E. Chiu MD Vice Chair, Professor in the Dermatology department at Medical College of WisconsinSara Sabbagh DO Associate Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AutoantibodiesChild
Dermatomyositis
Humans
Interferon Type I
Molecular Targeted Therapy
Phenotype
